Log In
BCIQ
Print this Print this
 

Px-104

  Manage Alerts
Collapse Summary General Information
Company Phenex Pharmaceuticals AG
DescriptionFarnesoid X receptor agonist
Molecular Target Farnesoid X receptor (FXR) (NR1H4)
Mechanism of ActionFarnesoid X receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$470.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/06/2015

Undisclosed

Undisclosed

$470.0M

Get a free BioCentury trial today